+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 123 Actively Recruiting clinical trials

S

Actively Recruiting

Healthy Volunteer

Researchers are studying the expression pattern of CD56, a marker found on natural killer cells and other immune cells, in patients with hematologic malignancies. These blood cancers arise from bone marrow or lymphatic system cells and include diverse diseases such as leukemia, lymphoma, and multiple myeloma. While CD56 overexpression has been linked to certain conditions like acute myeloid leukemia, this study aims to explore its pattern across various hematologic cancers. The study involves detecting CD56 expression using a diagnostic test called flow cytometry. Participants include newly diagnosed patients with hematologic malignancies and control healthy individuals. This observational study will compare CD56 expression between these groups without administering any treatment. During the study, participants will undergo the CD56 detection test and provide samples for analysis. Researchers will measure how CD56 is expressed in different blood cancers over one year. The study also monitors participant health and gathers data to better understand the role of CD56 in these diseases. The total duration involves initial testing and follow-up evaluations as needed.

All AgesAll Genders
2 locations
S

Actively Recruiting

Researchers are investigating ischemic stroke cases in patients who are on oral anticoagulants due to atrial fibrillation or other cardioembolic arrhythmias. This observational study, called ASPERA, aims to understand the characteristics of these stroke cases and to evaluate the short- and long-term outcomes of different strategies used to prevent recurrent strokes. The study includes both retrospective and prospective data collection from multiple centers worldwide, coordinated by the University of LAquila. The study has two parts ASPERA-R and ASPERA-P. ASPERA-R collects retrospective data over five years, focusing on baseline demographic, clinical, and neuroimaging features of ischemic strokes in patients on oral anticoagulants. ASPERA-P enrolls patients prospectively for two years with follow-up for five years to assess risks of stroke recurrence and safety events under different secondary prevention approaches, such as continuing or changing oral anticoagulation. Participants will have their data collected at several time points, including hospital admission, discharge, and follow-ups at 90 days, 1 year, and 5 years after stroke. Assessments include clinical evaluations, neuroimaging exams, and monitoring for stroke recurrence, bleeding events, heart attacks, and mortality. The study tracks outcomes to better understand risks and to identify features linked to stroke recurrence and safety events, with total participation lasting up to seven years for prospective patients.

Age: 18Years +All Genders
47 locations
E

Actively Recruiting

Researchers are studying the effectiveness of different nerve blocks and intrathecal morphine for managing pain after cesarean section surgery. The study aims to compare how long these methods provide pain relief after surgery in women aged 18 to 40 years who have elective cesarean deliveries. This randomized trial is sponsored by Assiut University and focuses on postoperative pain control. Participants are assigned to one of three groups one group receives intrathecal morphine with standard spinal anesthesia the second group receives the same spinal anesthesia plus a bilateral Quadratus Lumborum nerve block with bupivacaine and dexamethasone the third group receives spinal anesthesia plus a bilateral Erector Spinae nerve block with the same drugs. All treatments are given during cesarean section surgery. During the study, participants will be monitored to measure how long the pain relief lasts until the first request for additional pain medication within 24 hours after surgery. The trial follows participants through this period to assess and compare the duration of analgesia provided by each method. Safety and pain control will be closely observed throughout the study.

Age: 18Years - 40YearsFEMALEPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are investigating whether arterial stiffness, measured by Pulse Wave Velocity, can independently predict acute kidney injury in patients with sepsis. The study also compares Pulse Wave Velocity with shear wave ultrasound elastography as different ways to evaluate arterial stiffness in predicting this kidney complication. The research involves collecting detailed patient information including age, sex, medical history, and sepsis source. Clinical data like vital signs, fluid status, and lab tests such as blood counts and kidney function are recorded. Measurements of arterial stiffness using Pulse Wave Velocity and shear wave elastography are taken within the first 24 hours of ICU admission. Renal resistive index is also assessed using Doppler ultrasound. All assessments are done by trained examiners. Participants will be monitored through clinical exams, blood tests, ECG, echocardiography, and sepsis evaluations. Researchers will analyze these data to see how arterial stiffness relates to kidney injury in sepsis over a two-year period. The study tracks organ function scores and collects comprehensive cardiovascular and kidney-related measurements to understand this relationship better.

Age: 18Years +All Genders
1 location
S

Actively Recruiting

Researchers are evaluating the pain relief effects of two ultrasound-guided regional anesthesia techniques, the transversus thoracic muscle plane block TTPB and the pecto-intercostal fascial block PIFB, in patients undergoing open cardiac surgery. This study focuses on managing the significant pain that occurs after sternotomy, which is a common and painful part of cardiac surgery, especially within the first 24 hours post-operation. Participants will be randomly assigned to one of three groups receiving PIFB, receiving TTPB, or receiving a sham procedure with superficial saline injection. Both PIFB and TTPB blocks are performed intraoperatively using bupivacaine combined with dexamethasone to target nerves supplying the anterior chest wall. The sham group receives superficial needle punctures without active anesthetic injection. During the study, participants analgesic requirements, pain levels, need for rescue pain medication, nausea and vomiting, time to extubation, ICU stay duration, delirium assessment, patient satisfaction, and any complications will be monitored primarily within 24 hours and up to 7 days after surgery. The total participation lasts up to the completion of the postoperative assessments, with the primary outcomes focused on pain control and recovery measures after cardiac surgery.

Age: 40Years - 60YearsAll GendersPhase Not Applicable
1 location
N

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of preoperative intravenous and nebulized tranexamic acid on patients undergoing functional endoscopic sinus surgery FESS, a common treatment for conditions affecting the nasal cavity and paranasal sinuses. The study aims to assess how these treatments impact surgical field visibility using the Modena Bleeding Score, blood loss, anesthetic use, and patient hemodynamics. It also monitors potential postoperative complications such as nausea, vomiting, visual disturbances, seizures, and clotting events. Participants will receive either intravenous or nebulized tranexamic acid before surgery to compare their effects on controlling bleeding during FESS. Tranexamic acid works by inhibiting fibrinolysis, which helps reduce bleeding. The study evaluates the two methods of administration to determine which better improves the surgical experience for both surgeons and patients. Throughout the study, participants vital signs like blood pressure, respiratory rate, temperature, pulse, oxygen saturation, and end-tidal CO2 will be monitored. Researchers will measure intraoperative bleeding by blood volume collected and gauze count, track anesthetic consumption including extra doses of fentanyl, propofol, and sevoflurane, and observe any postoperative complications. The trial includes regular assessments to evaluate safety and effectiveness, with participation lasting through the surgical procedure and immediate recovery period.

Age: 18Years - 65YearsAll GendersEarly Phase 1
1 location
E

Actively Recruiting

This research aims to clinically evaluate patients with partial anterior cruciate ligament ACL tears who undergo ACL augmentation surgery. The study focuses on assessing knee function primarily using the International Knee Documentation Committee IKDC score to measure outcomes in these patients. The evaluation is conducted at Assiut University Hospital and sponsored by Assiut University. Patients in this study will receive ACL augmentation surgery using a hamstring graft. The graft is fixed to the femoral part with adjustable loop devices, while fixation to the tibial part is done using bio or peak screws, sometimes with additional staples. This procedure is designed for patients with partial ACL tears, including those with or without meniscal tears or knee deformities, and includes both recent and chronic injuries. During the study, participants will undergo clinical evaluations to record IKDC scores at baseline and follow-up to observe changes in knee function after surgery. The main outcome measured is the difference in IKDC scores from baseline. Participants will be monitored throughout the study period, which runs until March 2026, to assess the surgical outcomes and recovery progress.

Age: 15Years - 50YearsAll GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the therapeutic role of azithromycin in treating acute exacerbations of idiopathic pulmonary fibrosis AE-IPF. The trial is part of the Assiut University IPF Research Program and uses the SCALE-IPF framework to classify disease severity and the IPIM model for phenotyping patients. In September 2025, the study expanded into a multi-arm platform to also assess combination antifibrotic and immunomodulatory therapies, including pirfenidone with or without azithromycin, without changing the original study design or endpoints. Participants receive conventional treatment for AE-IPF, including pulse corticosteroids and oxygen therapy. Four study groups exist one receiving conventional therapy alone another receiving conventional therapy plus azithromycin a third receiving standard-dose pirfenidone and a fourth receiving pirfenidone combined with azithromycin. Azithromycin is given initially as a 500 mg daily dose for five days, then three times weekly during follow-up. Pirfenidone is administered orally at 801 mg three times daily according to standard dosing and safety monitoring. During the study, participants are monitored for hospital stay duration, clinical outcomes stratified by disease severity, one-year mortality, and event-free survival over 12 months. Researchers use clinical, functional, and radiological assessments based on the SCALE-IPF and IPIM frameworks to evaluate treatment effects. Safety monitoring and standard clinical evaluations occur throughout the follow-up period, which includes up to one year post-randomization.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
2 locations
A

Actively Recruiting

Researchers are evaluating azithromycins effect on adults with non-cystic fibrosis bronchiectasis NCFB in the AMBER trial. This phase 4, randomized, double-blind, placebo-controlled study aims to determine if taking azithromycin daily for 12 months, along with standard bronchiectasis care, reduces the chance of experiencing at least one bronchiectasis exacerbation compared to placebo. The study is conducted within the Assiut University bronchiectasis translational research platform and follows a parallel-group design. Participants are randomly assigned in equal groups to receive either 250 mg of azithromycin or a matching placebo once daily for 12 months, both alongside their usual bronchiectasis care. Standard care may include medications like mucolytics and bronchodilators, chest physiotherapy, patient education, airway-clearance support, and treatment for acute exacerbations as needed. The trial uses a concealed randomization method with quadruple masking to keep participants and study staff unaware of treatment assignments during the study. Throughout the 12-month follow-up, participants will undergo clinical, functional, radiological, inflammatory, and safety assessments. Researchers will monitor bronchiectasis exacerbations, lung function FEV1%, oxygen saturation, inflammation markers, symptom scales, and adverse events. The study evaluates both the occurrence and timing of exacerbations, hospitalizations, and changes in health questionnaires. Safety monitoring includes cardiac concerns, gastrointestinal intolerance, and treatment discontinuation. The total participation period is 12 months with planned thorough follow-up visits and assessments.

Age: 18Years +All GendersPhase 4
1 location
S

Actively Recruiting

Non-cystic fibrosis bronchiectasis NCFB is a chronic lung condition marked by permanent airway widening, poor mucus clearance, frequent infections, ongoing inflammation, and repeated flare-ups. Researchers are evaluating the Bronchiectasis Assessment of Severity and Exacerbations BASE framework to classify disease severity and predict the risk of flare-ups within 12 months using objective clinical and laboratory measures. The study is a prospective observational cohort aimed at developing and validating this new assessment tool for adults with NCFB. Participants will continue their usual medical care without any treatments assigned by the study. They will be divided into two groups a development cohort to create the BASE model, and a validation cohort to test the model without changes. Assessments include baseline clinical exams, lung function tests, chest imaging reviews, oxygen level measurements, and blood markers of inflammation. Follow-up will last for 12 months to track flare-ups, hospitalizations, lung function changes, inflammation levels, treatment changes, and clinical outcomes. During the study, participants will undergo regular evaluations and data collection to support the development and validation of the BASE framework. Researchers will measure the accuracy of the BASE model in classifying current disease severity and predicting future flare-up risk. Safety and health outcomes will be monitored throughout the year, with detailed data recorded at scheduled intervals. The studys goal is to provide a practical tool for managing NCFB severity and risk while patients receive their standard care.

Age: 18Years +All Genders
1 location

1-10 of 123

1